PERSIST-1: Phase III study of pacritinib versus best available therapy in patients with myelofibrosis


In this short video, expert Ruben Mesa of Mayo Clinic (AZ, USA) gives an overview of the results of the Phase III PERSIST-1 trial, which were presented at the 2015 Annual Meeting of the American Society for Clinical Oncology.

The trial investigated the use of the JAK2/FLT3 inhibitor pacritinib in patients with myelofibrosis. Having demonstrated promising results in Phase II, Phase III PERSIST-1 demonstrated that the agent was safe and efficacious, suggesting overall that pacritinib will be an important option for patient with myelofibrosis.